Total : 82 View more »
Medical device maker Medtronic Inc. reported a 38 percent drop in fiscal first-quarter earnings Tuesday due to restructuring charges and legal fees from a patent dispute. Without the charges, the company's results narrowly beat Wall Street expectations.
http://www.newsvine.com/_news/2009/08/25/3189377-medtronic-1q-profit-falls-38-pct-on-abbott-payment
As initial trials of implants to treat epilepsy come to an end, researchers are asking if brain activity data could be used to treat a variety of other
Medical device maker Medtronic Inc. said Monday it will consolidate into two operating groups to support its 'One Medtronic' initiative.
http://www.manufacturing.net/News-Medtronic-Consolidating-Operating-Groups-083109.aspx
Medical device maker Medtronic Inc. reported fiscal first-quarter earnings Tuesday that edged past Wall Street expectations, despite a 38 percent drop in profit due to restructuring charges and legal fees from a patent dispute.
Total : 161 View more »
Nov 05, 2009 (Fresh Brewed Media via COMTEX) --
Medtronic (MDT) was upgraded today by analysts at Credit Suisse and the stock is now at $38.32, up $1.77 (4.84%) on volume of 5,313,818 shares traded. The analysts upped MDT to Outperform from Neutral. Over the last 52 weeks the stock has ranged from a low of $24.06 to a high of $40.90. Medtronic stock has been showing support around $35.48 and resistance in the $37.42 range. Technical indicators for the stock are bullish and S&P gives MDT a positive 4 STARS (out of 5) buy ranking. If you are looking for a hedged play on MDT the stock seems like it could be a candidate for a February out-of-the-money bull-put credit spread below the 34 range.
ABR-Seven Summits Strategic Investments NewsBite Goto www.iotogo.com/18w1 for our free report titled, The 18 Ways To Know When It's Time To Dump A Stock
Tags: S&P
Companies: Medtronic, Inc. (MDT)
MINNEAPOLIS, Nov 06, 2009 (BUSINESS WIRE) --
Recognizing its significant contributions to increasing U.S. exports, Medtronic, Inc., (NYSE: MDT) received President Barack Obama's "E" Award on Thursday, Nov. 5. The ceremony, held in the U.S. Department of Commerce, was part of the District Export Council Conference in Washington D.C. The award recognized Medtronic and other individuals and companies for their efforts in promoting and increasing U.S. exports.
"We are pleased to receive this recognition. As one of America's success stories and a global leader in the medical device industry, our ability to enhance U.S. exports is significant," said Bill Hawkins, Medtronic chairman and CEO. "The President's recognition of the role Medtronic and our industry continues to play will further drive our efforts to improve healthcare for people around the world."
Created by President John F. Kennedy in 1961, the "E" and "E Star" Awards are presented each year to clients or partners of their local Commercial Service offices. Entrants are nominated by the local Department of Commerce offices with whom they work. The awards are the highest recognition any U.S. company or organization may receive for supporting U.S. exports.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology--alleviating pain, restoring health, and extending life for millions of people around the world.
SOURCE: Medtronic, Inc.
Medtronic, Inc. Jeff Warren, 763-505-2696 Investor Relations or Chuck Grothaus, 763-505-2614 Public Relations
Tags: ceo commercial conference contributions export health healthcare local medical nyse president technology washington
Companies: Medtronic, Inc. (MDT)
Oct 28, 2009 (Close-Up Media via COMTEX) --
Medtronic, Inc. has announced study results from an oral presentation at the International Diabetes Federation's World Diabetes Congress held in Montreal, Canada.
This scientific convention highlights the latest developments in clinical research aimed at improving diabetes management and outcomes.
In a release, the Company noted:
In an oral presentation entitled, "The Onset trial of sensor-enhanced CSII in children with new onset type 1 diabetes," results of a prospective, randomized, multi-center trial were shared. The physician-initiated study, performed in five pediatric centers, assessed whether children (ages 1-16) newly diagnosed with type 1 diabetes could achieve improved glycemic control using an insulin pump augmented with Personal continuous glucose monitoring (CGM), known as the MiniMed Paradigm REAL-Time System, compared to a control group using a conventional insulin pump with self monitoring of blood glucose (SMBG).
"It is quite evident that children with type 1 diabetes can benefit from using insulin pump therapy with real-time continuous glucose monitoring at the onset of their disease," said Thomas Danne, M.D., lead investigator and chief physician at the "Auf der Bult" Diabetes Center for Children and Adolescents in Hanover, Germany. "In fact, we noted evidence that reducing glycemic variability has an effect on the pancreas, preserving beta cell function, which likely will improve diabetes outcomes over the long-term in these children."
A total of 160 patients in this Medtronic-supported study were randomized to use conventional insulin pump therapy with SMBG or an insulin pump with Personal CGM for 12 months. Key results highlighted during the oral presentation include:
- Insulin pump therapy at diabetes onset results in lower A1C values (average blood glucose) compared to historical controls (the use of insulin injections during the first 12 months after diagnosis), and improves psychological well being.
- The sub-group of patients using Personal CGM regularly (at least one glucose sensor per week) experienced significantly lower A1C values (0.5 percent, p=0.032) during the first year compared to the conventional insulin pump group.
- There were significantly fewer episodes of severe hypoglycemia in patients using an insulin pump with Personal CGM compared to those using conventional insulin pumps.
- In patients using Personal CGM, more frequent glucose sensor use during the first year was associated with significantly less C-peptide loss, and C-peptide values at 12 months were significantly higher in adolescents (12-16 years). In addition, glycemic variability (calculated by mean amplitude glucose excursion, MAGE) was significantly lower compared to the group using a conventional insulin pump with SMBG.
The Onset trial, conducted in Austria, France, Germany, and Poland, adds to the growing body of evidence that demonstrates using Personal CGM on a regular basis improves glycemic control.
The MiniMed Paradigm REAL-Time System is the world's only system to integrate an insulin pump with Personal CGM. Patients using Personal CGM are able to view glucose sensor data and use this information to understand how diet, exercise, medications and lifestyle affect glucose levels. By viewing graphs and receiving alerts when glucose levels are becoming too high or too low, patients can make more informed therapy decisions to maintain near-normal the world leader in glucose control.
The Diabetes business at Medtronic provides diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software, as well as 24/7 consumer and professional service and support.
((Comments on this story may be sent to health@closeupmedia.com))
Tags: austria business canada children clinical congress consumer diabetes disease exercise france germany health montreal poland research science software trial
Companies: Medtronic, Inc. (MDT)
Oct 29, 2009 (Datamonitor via COMTEX) --
Medtronic, a medical technology company, has announced the CE Mark and international launch of the PoleStar N30 surgical MRI system, the latest in neuro oncology surgical solutions. The PoleStar N30 system has been submitted to the FDA for approval.
Providing real-time imaging in the operating room, the PoleStar surgical magnetic resonance imaging (MRI) provides surgeons with targeting and navigational accuracy despite the anatomy movement that may occur during a procedure, Medtronic said.
With intra-operative imaging information, neurosurgeons have more confidence to achieve maximum tumor resection, while avoiding critical areas of the brain. Use of the PoleStar system may also reduce the need for revision surgeries and the length of stay at the hospital for the patient, the company added.
Jim Cloar, vice president and general manager of the navigation division, part of the surgical technologies business at Medtronic, said: "This is the next generation of intra-operative MRI providing flexibility, enhanced ergonomics and confidence in the achievement of surgical goals.
"With its unique compact design, the PoleStar surgical MRI system allows neurosurgeons to benefit from intra-operative MRI without the compromises inherent in other systems, such as extensive renovation of the operating room or restrictions upon the surgeons' choice of instruments."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon
Tags: business medical president technology
Companies: Medtronic, Inc. (MDT)
Total : 9,018 View more »
Once a runaway leader in innovation, the world’s largest medical device company has lately suffered from public mistakes and a drought of new products.
Information about Medtronic, Inc., including our mission and technology, Investor Relations, Corporate Governance, Newsroom, Career Opportunities and Medtronic Foundation/Medtronic in the Community.
Medtronic, a Fridley, Minn.-based company, plans to buy property and break ground this fall on a $65-million headquarters facility. The future site of the 7618.049-square-meter building is presently a 291374.8-square meter city-owned golf course. Project ...
http://www.infolink.com.au/n/Medtronic-Plans-New-Facility-n758966
While documentation is a necessary deliverable for all companies, its value and contribution to bottomline business results is often underestimated and overlooked. For Medtronic, one of the world's most innovative medical device manufacturers, documentation is much more than a checkbox on a product
Total : 587,000 View more »
Medtronic is the leader in medical technology providing lifelong solutions for people with chronic pain.
Medtronic, Inc. (NYSE: MDT), based in Minneapolis, Minnesota, is the world 's largest medical technology company and is included in the list of Fortune 500 companies.
Capsule info for Medtronic, Inc. ... Need more? Get unbiased, in-depth information on public and private companies worldwide.
NEWS & INFO. Medtronic Diabetes voluntarily recalls "Lot 8" Quick-Set infusion sets; Thousands join the Medtronic family through the Medtronic Cares Program
As the world’s leading medical technology company, we provide lifelong solutions to people with chronic disease. Everything we do is deeply rooted in our mission—to alleviate pain, restore health, and extend life.
http://www.coroflot.com/public/job_details.asp?job_id=21003&job_category_id_14=14
Accountant Medtronic, MN - Saint Paul Accountant Requisition 64981 Category Finance... to business units and other intercompany accountants. Support the resolution process when questions... 6 Hours 37 Minutes ago
Main Category: Public Health Also Included In: Conferences Article Date: 13 Mar 2009 - 0:00 PDT Medtronic, Inc.